FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF	CHANGES IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Wingrove Theresa					2. Issuer Name and Ticker or Trading Symbol ImmunoGen, Inc. [IMGN]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify					
	(F MUNOGEN ITER STRE	•	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/20/2022						X	below)	REGULA	ATOR	below)		
(Street) WALTH		IA State)	02451 (Zip)	4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc Line)	,					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			ite	Execution Date,		Code (Ins	Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr.			and 5) Securities Beneficially Owned Follow		Form: I (D) or I		. Nature of ndirect Beneficial Ownership			
					Code V Amount (A) or P						Price	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Code	nsaction Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)			s security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	on Title	ļ,	Amount or Number of Shares		(Instr. 4)	on(s)		
Stock Option (Right to Buy)	\$4.55	05/20/2022		A		83,363		05/20/2022 ⁽¹⁾	02/07/20		nmon ock	83,363	\$0	83,363		D	
Stock Option (Right to Buy)	\$ 4.55	11/14/2022		A		166,725		11/14/2022 ⁽²⁾	02/07/20		nmon ock	166,725	\$0	250,088	8	D	

Explanation of Responses:

- 1. On February 7, 2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On May 20, 2022, certain performance criteria were met, resulting in the vesting of 25% of the performance stock option award.
- 2. On February 7, 2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. On November 14, 2022, certain performance criteria were met, resulting in the vesting of 50% of the performance stock option award.

/s/ Renee Lentini, Attorney-in-

Fact

** Signature of Reporting Person

12/27/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.